Verrica Pharmaceuticals Inc.
VRCA | NASDAQ
$4.66
+$0.17 (+3.79%)
Sep 22, 2026, 2:16 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 35.58M | 7.57M | 5.12M | 9.03M | 12M | n/a |
Cost of Revenue | 3.44M | 2.74M | 746K | 725K | 472K | 229K |
Gross Profit | 32.14M | 4.83M | 4.38M | 8.31M | 11.53M | -229K |
Operating Income | -11.94M | -65.92M | -65.76M | -21.3M | -30.91M | -40.18M |
Interest Income | 929K | 1.42M | 2.74M | 476K | 123K | 521K |
Pretax Income | -17.89M | -76.58M | -67M | -24.49M | -35.08M | -42.69M |
Net Income | -17.89M | -76.58M | -67M | -24.49M | -35.08M | -45.5M |
Selling & General & Admin | 35.22M | 58.82M | 47.31M | 17.41M | 26.98M | 24.51M |
Research & Development | 8.86M | 11.84M | 20.3M | 12.2M | 15.93M | 15.67M |
Other Expenses | n/a | 83K | 2.54M | n/a | -472K | -229K |
Operating Expenses | 44.08M | 70.75M | 70.14M | 29.6M | 42.44M | 39.95M |
Interest Expense | 7.74M | 9.41M | 3.96M | 2.17M | 4.3M | 3.03M |
Selling & Marketing Expenses | n/a | n/a | 3.5K | n/a | n/a | n/a |
Cost & Expenses | 47.52M | 73.49M | 70.88M | 30.33M | 42.91M | 40.18M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 10.65M | 5.18M | 4.53M | 3.42M | 2.7M | 2.5M |
Shares Outstanding (Diluted) | 10.65M | 5.18M | 4.53M | 3.42M | 2.7M | 2.5M |
EPS (Basic) | -1.68 | -14.78 | -14.78 | -7.17 | -12.97 | -17.08 |
EPS (Diluted) | -1.68 | -14.78 | -14.78 | -7.17 | -12.97 | -17.08 |
EBITDA | -9.36M | -65.9M | -62.2M | -21.6M | -30.31M | -39.43M |
EBIT | -10.14M | -67.17M | -63.03M | -22.32M | -30.79M | -39.66M |
Depreciation & Amortization | 781K | 1.27M | 836K | 718K | 472K | 229K |
Add to Watchlist
Select watchlists to add or remove VRCA